Moxifalon T (Moxifloxacin)

Moxifloxacin, the active ingredient in Moxifalon T, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It is indicated for the treatment of community‑acquired bacterial pneumonia, acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and skin and soft‑tissue infections in adults.

GNH USA supplies Moxifalon T as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable delivery across markets.

Moxifloxacin is a fluoroquinolone antibiotic that targets bacterial infections of the respiratory and skin systems. - Community‑acquired bacterial pneumonia: eradicates the causative pathogens and improves clinical outcomes. - Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting bacteria. - Acute bacterial exacerbation of chronic bronchitis: controls bacterial overgrowth and relieves symptoms. - Skin and soft‑tissue infections: treats susceptible Gram‑positive and Gram‑negative organisms in cellulitis and wound infections.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Tendon rupture: sudden pain or swelling, especially in the Achilles. - QT interval prolongation: risk of cardiac arrhythmia. - Severe allergic reaction (anaphylaxis): hives, swelling, or breathing difficulty.

When prescribing moxifloxacin, clinicians should consider several precautionary measures to minimize risks. - Assess renal and hepatic function: adjust use in patients with severe impairment. - Review patient history for tendon disorders: avoid in those with recent tendon injury. - Evaluate cardiac risk: avoid in patients with known QT prolongation or arrhythmias. - Avoid concomitant use with other QT‑prolonging drugs: monitor ECG if unavoidable. - Pregnancy and breastfeeding: use only if benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption; separate dosing by at least 2 hours. - Warfarin: may increase INR and bleeding risk; monitor coagulation parameters. - Theophylline: increased plasma levels leading to toxicity; consider dose adjustment.

Moderate Interactions (Monitor Closely): - QT‑prolonging agents (e.g., macrolides, other fluoroquinolones): additive cardiac risk; monitor ECG. - CYP1A2 inhibitors (e.g., fluvoxamine): may raise moxifloxacin concentrations. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened risk of central nervous system effects.